HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New three-step combo shows promise against tough head and neck cancer
Disease control OngoingThis study tests a three-step treatment for people with a type of head and neck cancer not caused by HPV. First, patients receive a drug called palbociclib before standard chemoradiation, then they get chemoradiation, and finally they take palbociclib again after treatment. The g…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 29, 2026 01:38 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new medicine, PF-08046032, alone and with another drug (sasanlimab) in adults with advanced lymphomas or solid tumors that have spread or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the c…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC
-
New combo therapy aims to shrink tough tumors
Disease control OngoingThis study tests a new drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC
-
New combo therapy aims to shrink head and neck tumors
Disease control OngoingThis study tests a new drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors. About 29 adults with incurable head and neck squamous cell carcinoma…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC
-
New hope for head and neck cancer patients who failed standard therapy
Disease control OngoingThis study tests a new drug called SI-B001 in 11 adults with advanced head and neck cancer that has returned or spread and no longer responds to standard treatments like immunotherapy or chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. Participan…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 01:36 UTC
-
New combo therapy aims to boost immune attack on head and neck tumors before surgery
Disease control OngoingThis early-phase study tests two drugs (LVGN7409 and LVGN3616 or nivolumab) given together before surgery in 27 adults with HPV-negative head and neck cancer. The goal is to see if the combination is safe and can increase immune cell activity in the tumor. Participants will have …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Apr 29, 2026 01:36 UTC
-
New drug combo aims to stop head and neck cancer recurrence
Disease control OngoingThis study tests whether adding lenvatinib to pembrolizumab (immunotherapy) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with advanced, PD-L1 positive cancer will receive either the combination or pembrolizumab alone as mai…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Apr 29, 2026 01:35 UTC
-
New combo therapy before surgery shows promise for tough head and neck cancers
Disease control OngoingThis study tests giving a short course of targeted radiation plus an immunotherapy drug (pembrolizumab) before surgery for people with advanced head and neck cancer that is not caused by HPV. The goal is to shrink or eliminate the tumor before surgery, and to see if this approach…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC